PreveCeutical Medical Inc.
PREV
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 456.82% | -63.76% | 82.04% | 77.67% | -58.47% |
| Depreciation & Amortization | 15.79% | 0.00% | 5.56% | 0.00% | 5.56% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 377.48% | -59.80% | 59.04% | 65.70% | -53.73% |
| Operating Income | -377.48% | 59.80% | -59.04% | -65.70% | 53.73% |
| Income Before Tax | -204.75% | 44.50% | -37.77% | -54.14% | 38.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -204.75% | 44.50% | -37.77% | -54.14% | 38.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -204.75% | 44.50% | -37.77% | -54.14% | 38.04% |
| EBIT | -377.48% | 59.80% | -59.04% | -65.70% | 53.73% |
| EBITDA | -384.21% | 60.27% | -59.96% | -66.94% | 54.19% |
| EPS Basic | -233.33% | 50.00% | -66.67% | -66.67% | 40.00% |
| Normalized Basic EPS | -200.00% | 50.00% | -50.00% | -50.00% | 33.33% |
| EPS Diluted | -233.33% | 50.00% | -66.67% | -66.67% | 40.00% |
| Normalized Diluted EPS | -200.00% | 50.00% | -50.00% | -50.00% | 33.33% |
| Average Basic Shares Outstanding | 0.15% | 0.15% | 0.31% | 0.31% | 0.00% |
| Average Diluted Shares Outstanding | 0.15% | 0.15% | 0.31% | 0.31% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |